Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
90 hedge funds and large institutions have $196M invested in Eiger BioPharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 13 closing their positions.
408% more call options, than puts
Call options by funds: $4.08M | Put options by funds: $803K
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 94 → 90 (-4)
5% less capital invested
Capital invested by funds: $207M → $196M (-$11.1M)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.86M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.22M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.07M |
| 4 |
Morgan Stanley
New York
|
+$506K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$477K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.4M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.47M |
| 3 |
Two Sigma Advisers
New York
|
-$1.36M |
| 4 |
Two Sigma Investments
New York
|
-$1.2M |
| 5 |
Millennium Management
New York
|
-$1.19M |
EIGR Hedge Fund Activity: Q2 2021 in Review
90 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2021, worth a combined $196M — down 5.4% from $207M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of EIGR and 9 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 35 added.
The largest buyer was Ameriprise, adding an estimated $8.86M. The largest seller was Citadel Advisors, exiting entirely with an estimated $7.4M sold.
- 90 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2021, down from 94 in Q1 2021.
- Funds reported $196M of Eiger BioPharmaceuticals, Inc. stock for Q2 2021, down 5.4% quarter-over-quarter.
- 9 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2021 and 13 closed out, a net change of -4 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2021 was Ameriprise, an estimated $8.86M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2021 was Citadel Advisors, an estimated $7.4M sold.
Based on aggregated 13F filings for Q2 2021.